Eli Lilly (LLY) Pulls Back -5% from Highs Ahead of Q2 Earnings
Key Takeaways
- Eli Lilly shares pulled back roughly 5% from early July all-time highs near $1,249, closing at $1,148.84 on July 31, as investors position ahead of the August 5 Q2 2026 earnings report.
- The core GLP-1 franchise — Mounjaro and Zepbound — generated $12.82 billion in combined Q1 revenue, about 65% of total sales, and remains the central driver of the investment thesis.
- Foundayo, Lilly's newly launched oral obesity pill, faces early prescription headwinds and intense competition from Novo Nordisk's oral Wegovy.
- Novo Nordisk filed a federal lawsuit in July alleging false advertising in Lilly's comparative drug campaigns, adding legal uncertainty to the competitive narrative.
- Wall Street remains broadly bullish, with a consensus Moderate Buy rating and an average price target of approximately $1,284 — though several firms have raised targets above $1,400.
Where LLY Stands in the Market Right Now
Eli Lilly and Company (LLY) enters August 2026 trading near $1,149 after retreating from its all-time closing high of $1,235.56 set on July 7. The stock is hovering just above its 50-day moving average of roughly $1,151, a closely watched technical level that has provided support during prior pullbacks. I also checked the technical picture using Tickeron’s AI Trend Prediction Engine to see how it lines up with recent momentum. The decline of approximately 5% over the trailing 30 days reflects a combination of profit-taking after a strong run, pre-earnings positioning, and emerging competitive and legal crosscurrents in the obesity drug market. With a market capitalization near $1.09 trillion and a forward price-to-earnings ratio around 41, LLY trades at a premium that leaves limited room for disappointment when it reports second-quarter results on August 5.
Understanding Eli Lilly’s Core Business and Competitive Position
Eli Lilly is a 150-year-old global pharmaceutical company headquartered in Indianapolis, Indiana, with a diversified portfolio spanning diabetes, obesity, oncology, immunology, and neuroscience. The company's modern growth story is anchored by its GLP-1 receptor agonist franchise: Mounjaro (tirzepatide) for type 2 diabetes and Zepbound (tirzepatide) for chronic weight management. Together, these two injectable therapies have reshaped the cardiometabolic treatment landscape and propelled Lilly to the forefront of the global obesity market, where it holds an estimated 60% revenue share against primary rival Novo Nordisk. Beyond GLP-1 therapies, Lilly's pipeline includes Kisunla for Alzheimer's disease, Jaypirca in oncology, and the next-generation obesity candidate retatrutide, which recently completed Phase 3 trials. The company has committed roughly $55 billion to U.S. manufacturing capacity to meet surging demand.
Key Events Shaping the Stock Recently
Several significant events have shaped investor sentiment over the past 30 days. On July 16, Lilly announced the acquisition of AtaiBeckley for up to $3.8 billion, extending its reach into psychedelic-based treatments for depression — a signal that management is actively diversifying the pipeline beyond metabolic disease. On July 30, Lilly and contract manufacturer Resilience unveiled a $750 million investment to expand U.S. production capacity for injectable devices, reinforcing confidence in sustained long-term demand. On the competitive front, Novo Nordisk filed a federal lawsuit on July 21 alleging that Lilly's advertising for Zepbound and Mounjaro uses outdated clinical comparisons to misleadingly claim superiority, and sought a preliminary injunction on July 24. Lilly has denied wrongdoing and stands by its SURMOUNT-5 trial data. Meanwhile, prescription data from IQVIA indicated that Foundayo, Lilly's oral GLP-1 pill launched in April, has posted flat weekly prescriptions for several weeks, trailing the launch trajectory of Novo Nordisk's oral Wegovy. On the policy side, the Medicare GLP-1 Bridge program took effect July 1, lowering copays for eligible Part D beneficiaries to $50 per month through 2027 — a structural tailwind for the entire obesity treatment category.
Looking Ahead to 2026 and Key Catalysts
The August 5 earnings report is the most immediate catalyst. Consensus estimates call for approximately $20.5 billion in revenue and $6.06 in earnings per share, though the market's true focus will be on management's full-year guidance — currently set at $82 billion to $85 billion in revenue — and any commentary on Foundayo's commercial trajectory. Beyond earnings, investors should monitor the progression of the Novo Nordisk advertising lawsuit, which could escalate into a preliminary injunction ruling affecting Lilly's marketing campaigns. On the competitive front, Viking Therapeutics plans to advance its oral GLP-1 candidate VK2735 into Phase 3 trials in Q4 2026, while Structure Therapeutics is expected to initiate late-stage studies of aleniglipron in the second half of the year. Retatrutide Phase 3 data, pending release, represents another potential catalyst that could extend Lilly's obesity franchise leadership. Macroeconomic risks, including potential shifts in employer coverage of GLP-1 drugs and upcoming Medicare price negotiation outcomes, add layers of uncertainty that warrant close attention. From what I see, monitoring these developments will be essential.
Trending AI Robots
For traders seeking data-driven approaches to navigate volatile markets, I often turn to Tickeron's Trending AI Robots page. It offers a curated window into hundreds of AI-powered trading bots that actively trade thousands of tickers, highlighting only the top-performing and most relevant ones. Bots vary by trading style, time horizon, and performance metrics, making it easier to find an approach that matches individual goals and complements my own research process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LLY's RSI Indicator recovers from overbought zone
The 10-day RSI Oscillator for LLY moved out of overbought territory on June 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 instances where the indicator moved out of the overbought zone. In of the 33 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for LLY turned negative on July 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
LLY moved below its 50-day moving average on August 03, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in of 374 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 303 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.847) is normal, around the industry mean (19.571). P/E Ratio (39.633) is within average values for comparable stocks, (30.717). Projected Growth (PEG Ratio) (1.559) is also within normal values, averaging (11.496). LLY has a moderately low Dividend Yield (0.006) as compared to the industry average of (0.031). LLY's P/S Ratio (13.870) is very high in comparison to the industry average of (4.050).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement